BeStock  
Stocks › Biotechnology › TRVI

Trevi Therapeutics TRVI

US equityMarket cap rank #2705Biotechnology
$13.35 −$0.37 (-2.70%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $13.35 0.00%
Open$13.58
Prev close$13.72
Day range$13.23 – $13.90
Volume2.09M
Market cap$1.90B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$24.49M-76.0% YoY
Net profit-$21.45M-81.8% YoY
Diluted EPS-$0.13-62.5% YoY
Free cash flow-$19.71M-81.0% YoY
Operating cash flow-$19.69M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-11.4MDec '24$-10.3MMar '25$-12.3MJun '25$-11.8MSep '25$-8.3MDec '25$-13.2MMar '26$-17.8MJun '26$-21.5MSep '26

Diluted EPS by quarter

-0.11Dec '24-0.09Mar '25-0.09Jun '25-0.08Sep '25-0.06Dec '25-0.09Mar '26-0.11Jun '26-0.13Sep '26

Free cash flow by quarter

$-9.6MDec '24$-13.5MMar '25$-10.1MJun '25$-10.9MSep '25$-7.6MDec '25$-16.8MMar '26$-17.6MJun '26$-19.7MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-24.7%
Return on assets-23.8%
Return on invested capital-28.4%
Current ratio38.86
Liabilities / assets2.6%
Cash & investments$299.41M
Total debt$187,000.00
Net cash (debt)$299.22M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $24.49M $20.51M $14.91M $49.33M $10.22M
Selling and Admin Expenses $5.42M $5.36M $4.97M $15.85M $4.03M
-General & Admin Expense $5.42M $5.36M $4.97M $15.85M $4.03M
Research & Development $19.06M $15.15M $9.94M $33.48M $6.19M
Operating Profit -$24.49M -$20.51M -$14.91M -$49.33M -$10.22M
Net Non-Operating Interest Income (Expense) $3.02M $2.70M $1.70M $6.54M $1.90M
Non-Operating Interest Income $3.02M $2.70M $1.70M $6.54M $1.90M
Other Income (Expense) -$3,000.00 -$3,000.00 $4,000.00 -$31,000.00 -$15,000.00
Other Non-Operating Income (Expenses) -$3,000.00 -$3,000.00 $4,000.00 -$31,000.00 -$15,000.00
Pretax Profit -$21.47M -$17.82M -$13.21M -$42.82M -$8.33M
Tax -$19,000.00 -$19,000.00 -$20,000.00 -$64,000.00 -$16,000.00
Net Profit -$21.45M -$17.80M -$13.19M -$42.76M -$8.32M
Profit from Continuing Operations -$21.45M -$17.80M -$13.19M -$42.76M -$8.32M
Net Income to Parent Company -$21.45M -$17.80M -$13.19M -$42.76M -$8.32M
Net Income to Common Stockholders -$21.45M -$17.80M -$13.19M -$42.76M -$8.32M
Basic EPS -$0.13 -$0.11 -$0.09 -$0.32 -$0.06
Diluted EPS -$0.13 -$0.11 -$0.09 -$0.32 -$0.06
Non-Operating Interest Expense – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $310.81M $330.52M $179.61M $193.44M $193.44M
Total Current Assets $305.80M $325.71M $176.12M $191.66M $191.66M
Cash and Cash Equivalents & Short-Term Investments $299.41M $318.87M $171.78M $188.26M $188.26M
-Cash and Cash Equivalents $27.85M $54.30M $19.41M $18.91M $18.91M
-Short Term Investments $271.56M $264.57M $152.37M $169.35M $169.35M
Prepaid Assets $3.58M $4.26M $2.22M $1.26M $1.26M
Other Current Assets $2.81M $2.57M $2.12M $2.13M $2.13M
Total Non-Current Assets $5.02M $4.81M $3.49M $1.78M $1.78M
Net PPE $813,000.00 $878,000.00 $875,000.00 $855,000.00 $855,000.00
-Gross PPE $813,000.00 $878,000.00 $875,000.00 $1.21M $1.21M
Other Non-Current Assets $4.20M $3.94M $2.61M $928,000.00 $928,000.00
Total Liabilities $8.06M $9.01M $7.48M $10.20M $10.20M
Total Current Liabilities $7.87M $8.74M $7.12M $9.75M $9.75M
Payables $1.51M $3.10M $2.22M $3.91M $3.91M
-Accounts Payable $1.51M $3.10M $2.22M $3.91M $3.91M
Current Accrued Expenses $3.53M $3.21M $3.31M $2.79M $2.79M
Short-Term Debt and Capital Lease Obligation $340,000.00 $329,000.00 $318,000.00 $307,000.00 $307,000.00
-Current Capital Lease Obligation $340,000.00 $329,000.00 $318,000.00 $307,000.00 $307,000.00
Total Non-Current Liabilities $187,000.00 $276,000.00 $364,000.00 $446,000.00 $446,000.00
Long Term Debt and Capital Lease Obligation $187,000.00 $276,000.00 $364,000.00 $446,000.00 $446,000.00
-Long Term Capital Lease Obligation $187,000.00 $276,000.00 $364,000.00 $446,000.00 $446,000.00
Total Equity $302.76M $321.51M $172.13M $183.24M $183.24M
Stockholders' Equity $302.76M $321.51M $172.13M $183.24M $183.24M
Capital Stock $143,000.00 $142,000.00 $128,000.00 $128,000.00 $128,000.00
-Common Stock $143,000.00 $142,000.00 $128,000.00 $128,000.00 $128,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $686.36M $682.58M $515.19M $512.77M $512.77M
Retained Earnings -$382.25M -$360.79M -$343.00M -$329.80M -$329.80M
Gains/Losses Not Affecting Retained Earnings -$1.50M -$425,000.00 -$190,000.00 $148,000.00 $148,000.00
-Accumulated Depreciation – – – -$359,000.00 -$359,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$19.69M -$17.43M -$16.69M -$42.09M -$7.63M
Net cash flow from continuing operations -$19.69M -$17.43M -$16.69M -$42.09M -$7.63M
Net Income from Continuing Operations -$21.45M -$17.80M -$13.19M -$42.76M -$8.32M
Depreciation & Depletion & Amortization $41,000.00 $34,000.00 $34,000.00 $144,000.00 $31,000.00
Other Non-Cash Items $101,000.00 $102,000.00 $105,000.00 $463,000.00 $133,000.00
Change in Working Capital -$829,000.00 -$2.52M -$5.40M -$3.49M -$274,000.00
-Change in Prepaid Assets -$994,000.00 -$2.93M -$2.84M -$1.48M $158,000.00
-Change in Payables and Accrued Expense $165,000.00 $409,000.00 -$2.56M -$2.01M -$432,000.00
Net cash flow from investing -$7.18M -$112.04M $16.97M -$94.11M -$30.61M
Net Cash Flow from Continuing Investing Activities -$7.18M -$112.04M $16.97M -$94.11M -$30.61M
Net PPE Purchase and Sale -$25,000.00 -$124,000.00 -$102,000.00 -$12,000.00 $0.00
Net Investment Purchase and Sale -$7.15M -$111.91M $17.07M -$94.10M -$30.61M
Financing Cash Flow $412,000.00 $164.36M $222,000.00 $121.01M $284,000.00
Net Cash Flow from Continuing Financing Activities $412,000.00 $164.36M $222,000.00 $121.01M $284,000.00
Net Issuance Payments Of Debt $0.00 $0.00 $0.00 -$11,000.00 $0.00
Net Common Stock Issuance $0.00 – – $108.15M $0.00
Proceeds from Stock Option Exercised $411,000.00 $1.79M $222,000.00 $12.95M $284,000.00
Net Other Financing Charges $1,000.00 – – -$84,000.00 $0.00
Ending Cash Balance $27.85M $54.30M $19.41M $18.91M $18.91M
Net Change in Cash -$26.45M $34.89M $498,000.00 -$15.18M -$37.96M
Beginning Cash Balance $54.30M $19.41M $18.91M $34.10M $56.87M
Free Cash Flow -$19.71M -$17.55M -$16.79M -$42.10M -$7.63M
Gain/Loss from Continuing Operations – – – $7,000.00 –

Discussion

No comments yet — be the first to weigh in on TRVI.

Sign in to join the discussion.

Scroll to Top